Pacira BioSciences (PCRX) Free Cash Flow (2010 - 2026)

Pacira BioSciences' Free Cash Flow history runs 17 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 9.64% year-over-year to $24.3 million; the TTM figure through Mar 2026 stood at $147.9 million (down 7.19% YoY), while the FY2025 annual figure was $150.5 million, down 15.79% from the prior year.
• Free Cash Flow was $24.3 million for Q1 2026 at Pacira BioSciences, down from $57.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $57.3 million in Q4 2025 to a low of $9.3 million in Q2 2025.
• Historically, Free Cash Flow has averaged $35.8 million across 5 years, with a median of $36.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 2429.54% in 2022, then plunged 83.21% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $36.5 million in 2022, then retreated by 7.26% to $33.9 million in 2023, then plunged by 32.4% to $22.9 million in 2024, then surged by 150.26% to $57.3 million in 2025, then tumbled by 57.59% to $24.3 million in 2026.
• The last three Free Cash Flow figures came in at $24.3 million (Q1 2026), $57.3 million (Q4 2025), and $57.0 million (Q3 2025), per Business Quant data.